Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives
Information source: Abbott
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obesity; Hypertension
Intervention: sibutramine (Drug); sibutramine (Drug); verapamil/trandolapril (Drug); metoprolol/HCT (Drug); felodipine/ramipril (Drug)
Phase: Phase 3
Sponsored by: Abbott
To study the effect of sibutramine treatment on weight reduction and blood pressure
improvement in three groups with antihypertensive therapy whose blood pressure was not
adequately controlled with antihypertensive combination treatment.
Official title: Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment
Systolic Blood Pressure
Diastolic Blood Pressure
Minimum age: 20 Years.
Maximum age: 65 Years.
- Treated essential hypertension.
- Obesity: BMI 27-35 kg/m2
- Secondary hypertension.
- Stage 3 hypertension.
- Secondary obesity; BMI > 35kg/m2.
- CAD; MI within past 6 months; NYHA stage 3 or 4 heart failure; tachyarrhythmia/atrial
- Kidney failure.
- Liver failure.
- Unstable DM.
- Severe chronic infectious disease.
- Alcohol or drug abuse.
- Psychosis or treatment with antidepressants or major tranquilizers
Locations and Contacts
Starting date: February 2002
Last updated: May 16, 2008